nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4D—Opioid Signalling—ADCY5—osteoporosis	0.00203	0.0101	CbGpPWpGaD
Roflumilast—PDE4D—G alpha (s) signalling events—CALCA—osteoporosis	0.00203	0.0101	CbGpPWpGaD
Roflumilast—PDE4A—Opioid Signalling—ADCY5—osteoporosis	0.00193	0.00963	CbGpPWpGaD
Roflumilast—PDE4A—G alpha (s) signalling events—CALCA—osteoporosis	0.00193	0.00963	CbGpPWpGaD
Roflumilast—PDE4D—G Protein Signaling Pathways—ADCY5—osteoporosis	0.00182	0.00906	CbGpPWpGaD
Roflumilast—PDE4B—Opioid Signalling—ADCY5—osteoporosis	0.00179	0.00891	CbGpPWpGaD
Roflumilast—PDE4B—G alpha (s) signalling events—CALCA—osteoporosis	0.00179	0.00891	CbGpPWpGaD
Roflumilast—PDE4A—G Protein Signaling Pathways—ADCY5—osteoporosis	0.00173	0.00862	CbGpPWpGaD
Roflumilast—PDE4C—Opioid Signalling—POMC—osteoporosis	0.00171	0.00855	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—CALCA—osteoporosis	0.0017	0.00846	CbGpPWpGaD
Roflumilast—PDE4C—G alpha (s) signalling events—ADCY5—osteoporosis	0.00166	0.00827	CbGpPWpGaD
Roflumilast—PDE4B—G Protein Signaling Pathways—ADCY5—osteoporosis	0.0016	0.00798	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—CALCA—osteoporosis	0.00149	0.00745	CbGpPWpGaD
Roflumilast—PDE4D—Opioid Signalling—POMC—osteoporosis	0.00149	0.00744	CbGpPWpGaD
Roflumilast—PDE4D—G alpha (s) signalling events—ADCY5—osteoporosis	0.00144	0.0072	CbGpPWpGaD
Roflumilast—Constipation—Ibandronate—osteoporosis	0.00144	0.0018	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00143	0.00179	CcSEcCtD
Roflumilast—Gastrointestinal pain—Estropipate—osteoporosis	0.00143	0.00179	CcSEcCtD
Roflumilast—Decreased appetite—Calcitriol—osteoporosis	0.00143	0.00179	CcSEcCtD
Roflumilast—Mental disorder—Conjugated Estrogens—osteoporosis	0.00143	0.00179	CcSEcCtD
Roflumilast—Back pain—Zoledronate—osteoporosis	0.00142	0.00178	CcSEcCtD
Roflumilast—Feeling abnormal—Alendronate—osteoporosis	0.00142	0.00178	CcSEcCtD
Roflumilast—PDE4A—Opioid Signalling—POMC—osteoporosis	0.00142	0.00708	CbGpPWpGaD
Roflumilast—Malnutrition—Conjugated Estrogens—osteoporosis	0.00142	0.00177	CcSEcCtD
Roflumilast—Muscle spasms—Zoledronate—osteoporosis	0.00142	0.00177	CcSEcCtD
Roflumilast—Urinary tract infection—Estradiol—osteoporosis	0.00141	0.00177	CcSEcCtD
Roflumilast—Gastrointestinal pain—Alendronate—osteoporosis	0.00141	0.00176	CcSEcCtD
Roflumilast—Infection—Ethinyl Estradiol—osteoporosis	0.00141	0.00176	CcSEcCtD
Roflumilast—Constipation—Calcitriol—osteoporosis	0.00141	0.00176	CcSEcCtD
Roflumilast—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00139	0.00174	CcSEcCtD
Roflumilast—Tension—Conjugated Estrogens—osteoporosis	0.00139	0.00174	CcSEcCtD
Roflumilast—Urticaria—Estropipate—osteoporosis	0.00139	0.00174	CcSEcCtD
Roflumilast—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00139	0.00174	CcSEcCtD
Roflumilast—Gastrointestinal pain—Raloxifene—osteoporosis	0.00139	0.00174	CcSEcCtD
Roflumilast—Diarrhoea—Etidronic acid—osteoporosis	0.00139	0.00173	CcSEcCtD
Roflumilast—Abdominal pain—Estropipate—osteoporosis	0.00138	0.00173	CcSEcCtD
Roflumilast—Feeling abnormal—Ibandronate—osteoporosis	0.00138	0.00173	CcSEcCtD
Roflumilast—Tremor—Zoledronate—osteoporosis	0.00138	0.00173	CcSEcCtD
Roflumilast—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00138	0.00172	CcSEcCtD
Roflumilast—Nervousness—Conjugated Estrogens—osteoporosis	0.00138	0.00172	CcSEcCtD
Roflumilast—Infection—Risedronate—osteoporosis	0.00138	0.00172	CcSEcCtD
Roflumilast—PDE4A—G alpha (s) signalling events—ADCY5—osteoporosis	0.00137	0.00685	CbGpPWpGaD
Roflumilast—Hepatobiliary disease—Estradiol—osteoporosis	0.00137	0.00172	CcSEcCtD
Roflumilast—Gastrointestinal pain—Ibandronate—osteoporosis	0.00137	0.00172	CcSEcCtD
Roflumilast—Myalgia—Pamidronate—osteoporosis	0.00137	0.00172	CcSEcCtD
Roflumilast—Back pain—Conjugated Estrogens—osteoporosis	0.00137	0.00172	CcSEcCtD
Roflumilast—Urticaria—Alendronate—osteoporosis	0.00137	0.00171	CcSEcCtD
Roflumilast—Anxiety—Pamidronate—osteoporosis	0.00137	0.00171	CcSEcCtD
Roflumilast—Ill-defined disorder—Zoledronate—osteoporosis	0.00137	0.00171	CcSEcCtD
Roflumilast—Abdominal pain—Alendronate—osteoporosis	0.00136	0.00171	CcSEcCtD
Roflumilast—Muscle spasms—Conjugated Estrogens—osteoporosis	0.00136	0.00171	CcSEcCtD
Roflumilast—Sinusitis—Estradiol—osteoporosis	0.00136	0.0017	CcSEcCtD
Roflumilast—Nervous system disorder—Risedronate—osteoporosis	0.00136	0.0017	CcSEcCtD
Roflumilast—Discomfort—Pamidronate—osteoporosis	0.00136	0.0017	CcSEcCtD
Roflumilast—Angioedema—Zoledronate—osteoporosis	0.00135	0.00168	CcSEcCtD
Roflumilast—Skin disorder—Risedronate—osteoporosis	0.00134	0.00168	CcSEcCtD
Roflumilast—Gastrointestinal pain—Calcitriol—osteoporosis	0.00134	0.00168	CcSEcCtD
Roflumilast—Abdominal pain—Raloxifene—osteoporosis	0.00134	0.00168	CcSEcCtD
Roflumilast—Urticaria—Ibandronate—osteoporosis	0.00133	0.00167	CcSEcCtD
Roflumilast—Malaise—Zoledronate—osteoporosis	0.00133	0.00166	CcSEcCtD
Roflumilast—Abdominal pain—Ibandronate—osteoporosis	0.00133	0.00166	CcSEcCtD
Roflumilast—Vertigo—Zoledronate—osteoporosis	0.00132	0.00165	CcSEcCtD
Roflumilast—PDE4B—Opioid Signalling—POMC—osteoporosis	0.00131	0.00655	CbGpPWpGaD
Roflumilast—Infection—Pamidronate—osteoporosis	0.00131	0.00164	CcSEcCtD
Roflumilast—Rhinitis—Estradiol—osteoporosis	0.00131	0.00163	CcSEcCtD
Roflumilast—Urticaria—Calcitriol—osteoporosis	0.00131	0.00163	CcSEcCtD
Roflumilast—Palpitations—Zoledronate—osteoporosis	0.0013	0.00163	CcSEcCtD
Roflumilast—Abdominal pain—Calcitriol—osteoporosis	0.0013	0.00163	CcSEcCtD
Roflumilast—Angioedema—Conjugated Estrogens—osteoporosis	0.0013	0.00162	CcSEcCtD
Roflumilast—Hypersensitivity—Estropipate—osteoporosis	0.00129	0.00161	CcSEcCtD
Roflumilast—Nervous system disorder—Pamidronate—osteoporosis	0.00129	0.00161	CcSEcCtD
Roflumilast—Vomiting—Etidronic acid—osteoporosis	0.00129	0.00161	CcSEcCtD
Roflumilast—Connective tissue disorder—Estradiol—osteoporosis	0.00128	0.0016	CcSEcCtD
Roflumilast—Rash—Etidronic acid—osteoporosis	0.00128	0.0016	CcSEcCtD
Roflumilast—Dermatitis—Etidronic acid—osteoporosis	0.00128	0.0016	CcSEcCtD
Roflumilast—Vertigo—Conjugated Estrogens—osteoporosis	0.00127	0.00159	CcSEcCtD
Roflumilast—Hypersensitivity—Alendronate—osteoporosis	0.00127	0.00159	CcSEcCtD
Roflumilast—PDE4B—G alpha (s) signalling events—ADCY5—osteoporosis	0.00127	0.00634	CbGpPWpGaD
Roflumilast—Headache—Etidronic acid—osteoporosis	0.00127	0.00159	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00126	0.00158	CcSEcCtD
Roflumilast—Asthenia—Estropipate—osteoporosis	0.00126	0.00157	CcSEcCtD
Roflumilast—Myalgia—Zoledronate—osteoporosis	0.00125	0.00157	CcSEcCtD
Roflumilast—Palpitations—Conjugated Estrogens—osteoporosis	0.00125	0.00157	CcSEcCtD
Roflumilast—Insomnia—Risedronate—osteoporosis	0.00125	0.00157	CcSEcCtD
Roflumilast—Anxiety—Zoledronate—osteoporosis	0.00125	0.00156	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—CALCR—osteoporosis	0.00125	0.00622	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PTH1R—osteoporosis	0.00125	0.00622	CbGpPWpGaD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00125	0.00156	CcSEcCtD
Roflumilast—Discomfort—Zoledronate—osteoporosis	0.00124	0.00155	CcSEcCtD
Roflumilast—Asthenia—Alendronate—osteoporosis	0.00124	0.00155	CcSEcCtD
Roflumilast—Hypersensitivity—Ibandronate—osteoporosis	0.00124	0.00155	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00123	0.00153	CcSEcCtD
Roflumilast—Fatigue—Ethinyl Estradiol—osteoporosis	0.00122	0.00153	CcSEcCtD
Roflumilast—PDE4C—G alpha (s) signalling events—POMC—osteoporosis	0.00122	0.00608	CbGpPWpGaD
Roflumilast—Dyspepsia—Risedronate—osteoporosis	0.00122	0.00152	CcSEcCtD
Roflumilast—Constipation—Ethinyl Estradiol—osteoporosis	0.00121	0.00152	CcSEcCtD
Roflumilast—Hypersensitivity—Calcitriol—osteoporosis	0.00121	0.00152	CcSEcCtD
Roflumilast—Cardiac disorder—Estradiol—osteoporosis	0.00121	0.00151	CcSEcCtD
Roflumilast—Myalgia—Conjugated Estrogens—osteoporosis	0.00121	0.00151	CcSEcCtD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—ADCY5—osteoporosis	0.00121	0.00602	CbGpPWpGaD
Roflumilast—Asthenia—Ibandronate—osteoporosis	0.0012	0.00151	CcSEcCtD
Roflumilast—Anxiety—Conjugated Estrogens—osteoporosis	0.0012	0.0015	CcSEcCtD
Roflumilast—Nausea—Etidronic acid—osteoporosis	0.0012	0.0015	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.0012	0.0015	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.0012	0.0015	CcSEcCtD
Roflumilast—Diarrhoea—Estropipate—osteoporosis	0.0012	0.0015	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Risedronate—osteoporosis	0.00119	0.00149	CcSEcCtD
Roflumilast—Infection—Zoledronate—osteoporosis	0.00119	0.00149	CcSEcCtD
Roflumilast—Fatigue—Risedronate—osteoporosis	0.00119	0.00149	CcSEcCtD
Roflumilast—Insomnia—Pamidronate—osteoporosis	0.00119	0.00149	CcSEcCtD
Roflumilast—Constipation—Risedronate—osteoporosis	0.00118	0.00148	CcSEcCtD
Roflumilast—Diarrhoea—Alendronate—osteoporosis	0.00118	0.00148	CcSEcCtD
Roflumilast—Asthenia—Calcitriol—osteoporosis	0.00118	0.00148	CcSEcCtD
Roflumilast—Nervous system disorder—Zoledronate—osteoporosis	0.00118	0.00147	CcSEcCtD
Roflumilast—Immune system disorder—Estradiol—osteoporosis	0.00118	0.00147	CcSEcCtD
Roflumilast—Mediastinal disorder—Estradiol—osteoporosis	0.00117	0.00147	CcSEcCtD
Roflumilast—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00117	0.00146	CcSEcCtD
Roflumilast—Skin disorder—Zoledronate—osteoporosis	0.00117	0.00146	CcSEcCtD
Roflumilast—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00116	0.00145	CcSEcCtD
Roflumilast—Diarrhoea—Raloxifene—osteoporosis	0.00116	0.00145	CcSEcCtD
Roflumilast—Dyspepsia—Pamidronate—osteoporosis	0.00116	0.00145	CcSEcCtD
Roflumilast—Dizziness—Estropipate—osteoporosis	0.00116	0.00145	CcSEcCtD
Roflumilast—Infection—Conjugated Estrogens—osteoporosis	0.00115	0.00144	CcSEcCtD
Roflumilast—Diarrhoea—Ibandronate—osteoporosis	0.00115	0.00144	CcSEcCtD
Roflumilast—Decreased appetite—Pamidronate—osteoporosis	0.00114	0.00143	CcSEcCtD
Roflumilast—Mental disorder—Estradiol—osteoporosis	0.00114	0.00143	CcSEcCtD
Roflumilast—Dizziness—Alendronate—osteoporosis	0.00114	0.00143	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00114	0.00142	CcSEcCtD
Roflumilast—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00113	0.00142	CcSEcCtD
Roflumilast—Malnutrition—Estradiol—osteoporosis	0.00113	0.00142	CcSEcCtD
Roflumilast—Fatigue—Pamidronate—osteoporosis	0.00113	0.00142	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—CALCR—osteoporosis	0.00113	0.00565	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PTH1R—osteoporosis	0.00113	0.00565	CbGpPWpGaD
Roflumilast—Gastrointestinal pain—Risedronate—osteoporosis	0.00113	0.00142	CcSEcCtD
Roflumilast—Urticaria—Ethinyl Estradiol—osteoporosis	0.00113	0.00141	CcSEcCtD
Roflumilast—Constipation—Pamidronate—osteoporosis	0.00113	0.00141	CcSEcCtD
Roflumilast—Diarrhoea—Calcitriol—osteoporosis	0.00112	0.00141	CcSEcCtD
Roflumilast—Skin disorder—Conjugated Estrogens—osteoporosis	0.00112	0.00141	CcSEcCtD
Roflumilast—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00112	0.0014	CcSEcCtD
Roflumilast—Dizziness—Raloxifene—osteoporosis	0.00112	0.0014	CcSEcCtD
Roflumilast—Tension—Estradiol—osteoporosis	0.00111	0.00139	CcSEcCtD
Roflumilast—Vomiting—Estropipate—osteoporosis	0.00111	0.00139	CcSEcCtD
Roflumilast—Dysgeusia—Estradiol—osteoporosis	0.00111	0.00139	CcSEcCtD
Roflumilast—Dizziness—Ibandronate—osteoporosis	0.00111	0.00139	CcSEcCtD
Roflumilast—Rash—Estropipate—osteoporosis	0.0011	0.00138	CcSEcCtD
Roflumilast—Dermatitis—Estropipate—osteoporosis	0.0011	0.00138	CcSEcCtD
Roflumilast—Nervousness—Estradiol—osteoporosis	0.0011	0.00138	CcSEcCtD
Roflumilast—Urticaria—Risedronate—osteoporosis	0.0011	0.00138	CcSEcCtD
Roflumilast—Back pain—Estradiol—osteoporosis	0.0011	0.00137	CcSEcCtD
Roflumilast—Headache—Estropipate—osteoporosis	0.0011	0.00137	CcSEcCtD
Roflumilast—Vomiting—Alendronate—osteoporosis	0.0011	0.00137	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00109	0.00137	CcSEcCtD
Roflumilast—Abdominal pain—Risedronate—osteoporosis	0.00109	0.00137	CcSEcCtD
Roflumilast—Muscle spasms—Estradiol—osteoporosis	0.00109	0.00136	CcSEcCtD
Roflumilast—Rash—Alendronate—osteoporosis	0.00109	0.00136	CcSEcCtD
Roflumilast—Insomnia—Zoledronate—osteoporosis	0.00109	0.00136	CcSEcCtD
Roflumilast—Dermatitis—Alendronate—osteoporosis	0.00109	0.00136	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—PTH1R—osteoporosis	0.00109	0.00542	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CALCR—osteoporosis	0.00109	0.00542	CbGpPWpGaD
Roflumilast—Feeling abnormal—Pamidronate—osteoporosis	0.00108	0.00136	CcSEcCtD
Roflumilast—Headache—Alendronate—osteoporosis	0.00108	0.00135	CcSEcCtD
Roflumilast—Vomiting—Raloxifene—osteoporosis	0.00108	0.00135	CcSEcCtD
Roflumilast—Gastrointestinal pain—Pamidronate—osteoporosis	0.00108	0.00135	CcSEcCtD
Roflumilast—Rash—Raloxifene—osteoporosis	0.00107	0.00134	CcSEcCtD
Roflumilast—Dermatitis—Raloxifene—osteoporosis	0.00107	0.00134	CcSEcCtD
Roflumilast—Vomiting—Ibandronate—osteoporosis	0.00107	0.00134	CcSEcCtD
Roflumilast—Tremor—Estradiol—osteoporosis	0.00106	0.00133	CcSEcCtD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—ADCY5—osteoporosis	0.00106	0.0053	CbGpPWpGaD
Roflumilast—Headache—Raloxifene—osteoporosis	0.00106	0.00133	CcSEcCtD
Roflumilast—PDE4D—G alpha (s) signalling events—POMC—osteoporosis	0.00106	0.00529	CbGpPWpGaD
Roflumilast—Rash—Ibandronate—osteoporosis	0.00106	0.00132	CcSEcCtD
Roflumilast—Dermatitis—Ibandronate—osteoporosis	0.00106	0.00132	CcSEcCtD
Roflumilast—Dyspepsia—Zoledronate—osteoporosis	0.00106	0.00132	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00105	0.00132	CcSEcCtD
Roflumilast—Ill-defined disorder—Estradiol—osteoporosis	0.00105	0.00132	CcSEcCtD
Roflumilast—Headache—Ibandronate—osteoporosis	0.00105	0.00132	CcSEcCtD
Roflumilast—Insomnia—Conjugated Estrogens—osteoporosis	0.00105	0.00131	CcSEcCtD
Roflumilast—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00105	0.00131	CcSEcCtD
Roflumilast—Vomiting—Calcitriol—osteoporosis	0.00105	0.00131	CcSEcCtD
Roflumilast—Decreased appetite—Zoledronate—osteoporosis	0.00104	0.00131	CcSEcCtD
Roflumilast—Nausea—Estropipate—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Abdominal pain—Pamidronate—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Angioedema—Estradiol—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Rash—Calcitriol—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Fatigue—Zoledronate—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—Dermatitis—Calcitriol—osteoporosis	0.00104	0.0013	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—PTH1R—osteoporosis	0.00103	0.00515	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CALCR—osteoporosis	0.00103	0.00515	CbGpPWpGaD
Roflumilast—Headache—Calcitriol—osteoporosis	0.00103	0.00129	CcSEcCtD
Roflumilast—Constipation—Zoledronate—osteoporosis	0.00103	0.00129	CcSEcCtD
Roflumilast—Nausea—Alendronate—osteoporosis	0.00102	0.00128	CcSEcCtD
Roflumilast—Malaise—Estradiol—osteoporosis	0.00102	0.00128	CcSEcCtD
Roflumilast—Hypersensitivity—Risedronate—osteoporosis	0.00102	0.00128	CcSEcCtD
Roflumilast—Vertigo—Estradiol—osteoporosis	0.00102	0.00128	CcSEcCtD
Roflumilast—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00102	0.00127	CcSEcCtD
Roflumilast—Asthenia—Ethinyl Estradiol—osteoporosis	0.00102	0.00127	CcSEcCtD
Roflumilast—PDE4D—TSH signaling pathway—MYC—osteoporosis	0.00102	0.00507	CbGpPWpGaD
Roflumilast—PDE4A—G alpha (s) signalling events—POMC—osteoporosis	0.00101	0.00504	CbGpPWpGaD
Roflumilast—Nausea—Raloxifene—osteoporosis	0.00101	0.00126	CcSEcCtD
Roflumilast—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00101	0.00126	CcSEcCtD
Roflumilast—Palpitations—Estradiol—osteoporosis	0.001	0.00125	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000999	0.00125	CcSEcCtD
Roflumilast—Fatigue—Conjugated Estrogens—osteoporosis	0.000998	0.00125	CcSEcCtD
Roflumilast—Nausea—Ibandronate—osteoporosis	0.000998	0.00125	CcSEcCtD
Roflumilast—Asthenia—Risedronate—osteoporosis	0.000993	0.00124	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—MGLL—osteoporosis	0.000991	0.00494	CbGpPWpGaD
Roflumilast—Feeling abnormal—Zoledronate—osteoporosis	0.00099	0.00124	CcSEcCtD
Roflumilast—Constipation—Conjugated Estrogens—osteoporosis	0.00099	0.00124	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—PTH1R—osteoporosis	0.000986	0.00492	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CALCR—osteoporosis	0.000986	0.00492	CbGpPWpGaD
Roflumilast—Gastrointestinal pain—Zoledronate—osteoporosis	0.000983	0.00123	CcSEcCtD
Roflumilast—Nausea—Calcitriol—osteoporosis	0.000977	0.00122	CcSEcCtD
Roflumilast—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000971	0.00121	CcSEcCtD
Roflumilast—Hypersensitivity—Pamidronate—osteoporosis	0.000969	0.00121	CcSEcCtD
Roflumilast—Myalgia—Estradiol—osteoporosis	0.000966	0.00121	CcSEcCtD
Roflumilast—Anxiety—Estradiol—osteoporosis	0.000963	0.0012	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000959	0.0012	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—CALCR—osteoporosis	0.000957	0.00477	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PTH1R—osteoporosis	0.000957	0.00477	CbGpPWpGaD
Roflumilast—Urticaria—Zoledronate—osteoporosis	0.000955	0.00119	CcSEcCtD
Roflumilast—Discomfort—Estradiol—osteoporosis	0.000955	0.00119	CcSEcCtD
Roflumilast—Abdominal pain—Zoledronate—osteoporosis	0.00095	0.00119	CcSEcCtD
Roflumilast—Diarrhoea—Risedronate—osteoporosis	0.000947	0.00118	CcSEcCtD
Roflumilast—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000946	0.00118	CcSEcCtD
Roflumilast—Asthenia—Pamidronate—osteoporosis	0.000944	0.00118	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—PTH1R—osteoporosis	0.000939	0.00468	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CALCR—osteoporosis	0.000939	0.00468	CbGpPWpGaD
Roflumilast—Dizziness—Ethinyl Estradiol—osteoporosis	0.000939	0.00117	CcSEcCtD
Roflumilast—PDE4B—G alpha (s) signalling events—POMC—osteoporosis	0.000935	0.00466	CbGpPWpGaD
Roflumilast—Infection—Estradiol—osteoporosis	0.00092	0.00115	CcSEcCtD
Roflumilast—Urticaria—Conjugated Estrogens—osteoporosis	0.000919	0.00115	CcSEcCtD
Roflumilast—Dizziness—Risedronate—osteoporosis	0.000915	0.00114	CcSEcCtD
Roflumilast—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000915	0.00114	CcSEcCtD
Roflumilast—Nervous system disorder—Estradiol—osteoporosis	0.000908	0.00114	CcSEcCtD
Roflumilast—Vomiting—Ethinyl Estradiol—osteoporosis	0.000903	0.00113	CcSEcCtD
Roflumilast—Diarrhoea—Pamidronate—osteoporosis	0.0009	0.00113	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—MGLL—osteoporosis	0.0009	0.00449	CbGpPWpGaD
Roflumilast—Skin disorder—Estradiol—osteoporosis	0.0009	0.00113	CcSEcCtD
Roflumilast—Rash—Ethinyl Estradiol—osteoporosis	0.000895	0.00112	CcSEcCtD
Roflumilast—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000894	0.00112	CcSEcCtD
Roflumilast—Headache—Ethinyl Estradiol—osteoporosis	0.000889	0.00111	CcSEcCtD
Roflumilast—Hypersensitivity—Zoledronate—osteoporosis	0.000885	0.00111	CcSEcCtD
Roflumilast—Vomiting—Risedronate—osteoporosis	0.00088	0.0011	CcSEcCtD
Roflumilast—Rash—Risedronate—osteoporosis	0.000873	0.00109	CcSEcCtD
Roflumilast—Dermatitis—Risedronate—osteoporosis	0.000872	0.00109	CcSEcCtD
Roflumilast—Dizziness—Pamidronate—osteoporosis	0.00087	0.00109	CcSEcCtD
Roflumilast—PDE4B—Signaling by GPCR—PTH1R—osteoporosis	0.000869	0.00433	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CALCR—osteoporosis	0.000869	0.00433	CbGpPWpGaD
Roflumilast—Headache—Risedronate—osteoporosis	0.000867	0.00108	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—MGLL—osteoporosis	0.000863	0.0043	CbGpPWpGaD
Roflumilast—Asthenia—Zoledronate—osteoporosis	0.000862	0.00108	CcSEcCtD
Roflumilast—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000853	0.00107	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000844	0.00106	CcSEcCtD
Roflumilast—Nausea—Ethinyl Estradiol—osteoporosis	0.000843	0.00105	CcSEcCtD
Roflumilast—Insomnia—Estradiol—osteoporosis	0.000838	0.00105	CcSEcCtD
Roflumilast—Vomiting—Pamidronate—osteoporosis	0.000837	0.00105	CcSEcCtD
Roflumilast—Asthenia—Conjugated Estrogens—osteoporosis	0.00083	0.00104	CcSEcCtD
Roflumilast—Rash—Pamidronate—osteoporosis	0.00083	0.00104	CcSEcCtD
Roflumilast—Dermatitis—Pamidronate—osteoporosis	0.000829	0.00104	CcSEcCtD
Roflumilast—Headache—Pamidronate—osteoporosis	0.000824	0.00103	CcSEcCtD
Roflumilast—Diarrhoea—Zoledronate—osteoporosis	0.000822	0.00103	CcSEcCtD
Roflumilast—Nausea—Risedronate—osteoporosis	0.000822	0.00103	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—MGLL—osteoporosis	0.000821	0.0041	CbGpPWpGaD
Roflumilast—Dyspepsia—Estradiol—osteoporosis	0.000815	0.00102	CcSEcCtD
Roflumilast—Decreased appetite—Estradiol—osteoporosis	0.000805	0.00101	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Estradiol—osteoporosis	0.0008	0.001	CcSEcCtD
Roflumilast—Fatigue—Estradiol—osteoporosis	0.000799	0.000999	CcSEcCtD
Roflumilast—Dizziness—Zoledronate—osteoporosis	0.000795	0.000994	CcSEcCtD
Roflumilast—Constipation—Estradiol—osteoporosis	0.000792	0.000991	CcSEcCtD
Roflumilast—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000792	0.00099	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—MGLL—osteoporosis	0.000784	0.00391	CbGpPWpGaD
Roflumilast—Nausea—Pamidronate—osteoporosis	0.000782	0.000978	CcSEcCtD
Roflumilast—Dizziness—Conjugated Estrogens—osteoporosis	0.000765	0.000957	CcSEcCtD
Roflumilast—Vomiting—Zoledronate—osteoporosis	0.000764	0.000956	CcSEcCtD
Roflumilast—Feeling abnormal—Estradiol—osteoporosis	0.000763	0.000955	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—MGLL—osteoporosis	0.00076	0.00379	CbGpPWpGaD
Roflumilast—Rash—Zoledronate—osteoporosis	0.000758	0.000948	CcSEcCtD
Roflumilast—Gastrointestinal pain—Estradiol—osteoporosis	0.000757	0.000947	CcSEcCtD
Roflumilast—Dermatitis—Zoledronate—osteoporosis	0.000757	0.000947	CcSEcCtD
Roflumilast—Headache—Zoledronate—osteoporosis	0.000753	0.000942	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—MGLL—osteoporosis	0.000746	0.00372	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SOST—osteoporosis	0.00074	0.00369	CbGpPWpGaD
Roflumilast—Vomiting—Conjugated Estrogens—osteoporosis	0.000736	0.00092	CcSEcCtD
Roflumilast—Urticaria—Estradiol—osteoporosis	0.000736	0.00092	CcSEcCtD
Roflumilast—Abdominal pain—Estradiol—osteoporosis	0.000732	0.000916	CcSEcCtD
Roflumilast—Rash—Conjugated Estrogens—osteoporosis	0.00073	0.000913	CcSEcCtD
Roflumilast—Dermatitis—Conjugated Estrogens—osteoporosis	0.000729	0.000912	CcSEcCtD
Roflumilast—Headache—Conjugated Estrogens—osteoporosis	0.000725	0.000907	CcSEcCtD
Roflumilast—Nausea—Zoledronate—osteoporosis	0.000714	0.000893	CcSEcCtD
Roflumilast—PDE4B—Signaling by GPCR—MGLL—osteoporosis	0.00069	0.00344	CbGpPWpGaD
Roflumilast—Nausea—Conjugated Estrogens—osteoporosis	0.000687	0.00086	CcSEcCtD
Roflumilast—Hypersensitivity—Estradiol—osteoporosis	0.000682	0.000854	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—CALCR—osteoporosis	0.000669	0.00334	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTH1R—osteoporosis	0.000669	0.00334	CbGpPWpGaD
Roflumilast—Asthenia—Estradiol—osteoporosis	0.000665	0.000831	CcSEcCtD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL1B—osteoporosis	0.000659	0.00329	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PTH—osteoporosis	0.000655	0.00327	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SOST—osteoporosis	0.000644	0.00321	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CNR2—osteoporosis	0.000639	0.00318	CbGpPWpGaD
Roflumilast—Diarrhoea—Estradiol—osteoporosis	0.000634	0.000793	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—SOST—osteoporosis	0.000613	0.00306	CbGpPWpGaD
Roflumilast—Dizziness—Estradiol—osteoporosis	0.000612	0.000766	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—PTH—osteoporosis	0.000595	0.00297	CbGpPWpGaD
Roflumilast—Vomiting—Estradiol—osteoporosis	0.000589	0.000737	CcSEcCtD
Roflumilast—Rash—Estradiol—osteoporosis	0.000584	0.00073	CcSEcCtD
Roflumilast—Dermatitis—Estradiol—osteoporosis	0.000583	0.00073	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—PTH1R—osteoporosis	0.000583	0.00291	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CALCR—osteoporosis	0.000583	0.00291	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL1B—osteoporosis	0.00058	0.00289	CbGpPWpGaD
Roflumilast—Headache—Estradiol—osteoporosis	0.00058	0.000726	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—CNR2—osteoporosis	0.00058	0.00289	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PTH—osteoporosis	0.000571	0.00284	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SOST—osteoporosis	0.000567	0.00283	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CNR2—osteoporosis	0.000556	0.00277	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTH1R—osteoporosis	0.000555	0.00277	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CALCR—osteoporosis	0.000555	0.00277	CbGpPWpGaD
Roflumilast—Nausea—Estradiol—osteoporosis	0.00055	0.000688	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—WNT1—osteoporosis	0.000545	0.00272	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PTH—osteoporosis	0.000543	0.00271	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PTHLH—osteoporosis	0.000543	0.00271	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MGLL—osteoporosis	0.000532	0.00265	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CNR2—osteoporosis	0.000529	0.00264	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LRP5—osteoporosis	0.000519	0.00259	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PTH—osteoporosis	0.000518	0.00258	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTH1R—osteoporosis	0.000513	0.00256	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CALCR—osteoporosis	0.000513	0.00256	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CNR2—osteoporosis	0.000505	0.00252	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PTH—osteoporosis	0.000502	0.00251	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LRP6—osteoporosis	0.000496	0.00248	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PTH—osteoporosis	0.000493	0.00246	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PTHLH—osteoporosis	0.000493	0.00246	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CNR2—osteoporosis	0.00049	0.00244	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CNR2—osteoporosis	0.000481	0.0024	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CALCA—osteoporosis	0.000478	0.00238	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—WNT1—osteoporosis	0.000475	0.00237	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PTHLH—osteoporosis	0.000473	0.00236	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MGLL—osteoporosis	0.000463	0.00231	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PTH—osteoporosis	0.000456	0.00228	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—WNT1—osteoporosis	0.000452	0.00225	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LRP5—osteoporosis	0.000452	0.00225	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PTHLH—osteoporosis	0.00045	0.00224	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CNR2—osteoporosis	0.000445	0.00222	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MGLL—osteoporosis	0.000441	0.0022	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CALCA—osteoporosis	0.000434	0.00216	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LRP6—osteoporosis	0.000432	0.00215	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LRP5—osteoporosis	0.00043	0.00214	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PTHLH—osteoporosis	0.000429	0.00214	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TLN1—osteoporosis	0.000419	0.00209	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—WNT1—osteoporosis	0.000418	0.00208	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PTHLH—osteoporosis	0.000416	0.00208	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CALCA—osteoporosis	0.000416	0.00208	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LRP6—osteoporosis	0.000411	0.00205	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PTHLH—osteoporosis	0.000409	0.00204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MGLL—osteoporosis	0.000408	0.00203	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LRP5—osteoporosis	0.000398	0.00198	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CALCA—osteoporosis	0.000396	0.00198	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL6—osteoporosis	0.000386	0.00192	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LRP6—osteoporosis	0.000381	0.0019	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PTHLH—osteoporosis	0.000378	0.00189	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CALCA—osteoporosis	0.000378	0.00188	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CALCA—osteoporosis	0.000367	0.00183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TLN1—osteoporosis	0.000365	0.00182	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—P4HB—osteoporosis	0.000361	0.0018	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CALCA—osteoporosis	0.00036	0.00179	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTH—osteoporosis	0.000352	0.00175	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TLN1—osteoporosis	0.000347	0.00173	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RAP1A—osteoporosis	0.000346	0.00172	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CNR2—osteoporosis	0.000343	0.00171	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—ADCY5—osteoporosis	0.00034	0.0017	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—osteoporosis	0.00034	0.00169	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NFATC1—osteoporosis	0.000337	0.00168	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—DKK1—osteoporosis	0.000334	0.00167	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CALCA—osteoporosis	0.000333	0.00166	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—WNT1—osteoporosis	0.000322	0.00161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TLN1—osteoporosis	0.000321	0.0016	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—P4HB—osteoporosis	0.000315	0.00157	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FGA—osteoporosis	0.000313	0.00156	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—ADCY5—osteoporosis	0.000309	0.00154	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTH—osteoporosis	0.000306	0.00153	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RAP1A—osteoporosis	0.000301	0.0015	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—P4HB—osteoporosis	0.000299	0.00149	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CNR2—osteoporosis	0.000298	0.00149	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—ADCY5—osteoporosis	0.000296	0.00148	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NFATC1—osteoporosis	0.000293	0.00146	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTH—osteoporosis	0.000291	0.00145	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTHLH—osteoporosis	0.000291	0.00145	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BMP2—osteoporosis	0.000291	0.00145	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—DKK1—osteoporosis	0.000291	0.00145	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RAP1A—osteoporosis	0.000286	0.00143	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FGB—osteoporosis	0.000285	0.00142	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CNR2—osteoporosis	0.000284	0.00142	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—ADCY5—osteoporosis	0.000282	0.00141	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—WNT1—osteoporosis	0.00028	0.0014	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NFATC1—osteoporosis	0.000279	0.00139	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—P4HB—osteoporosis	0.000277	0.00138	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—DKK1—osteoporosis	0.000277	0.00138	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PSMA2—osteoporosis	0.000275	0.00137	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PSMA5—osteoporosis	0.000275	0.00137	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGA—osteoporosis	0.000273	0.00136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTH—osteoporosis	0.00027	0.00134	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—ADCY5—osteoporosis	0.000269	0.00134	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—WNT1—osteoporosis	0.000267	0.00133	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RAP1A—osteoporosis	0.000265	0.00132	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CNR2—osteoporosis	0.000263	0.00131	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—ADCY5—osteoporosis	0.000261	0.0013	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGA—osteoporosis	0.00026	0.00129	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NFATC1—osteoporosis	0.000258	0.00129	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CALCA—osteoporosis	0.000256	0.00128	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—DKK1—osteoporosis	0.000256	0.00128	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ADCY5—osteoporosis	0.000256	0.00128	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTHLH—osteoporosis	0.000254	0.00126	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BMP2—osteoporosis	0.000254	0.00126	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—POMC—osteoporosis	0.00025	0.00125	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGB—osteoporosis	0.000248	0.00124	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—WNT1—osteoporosis	0.000247	0.00123	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTHLH—osteoporosis	0.000241	0.0012	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BMP2—osteoporosis	0.000241	0.0012	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGA—osteoporosis	0.00024	0.0012	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PSMA2—osteoporosis	0.00024	0.00119	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PSMA5—osteoporosis	0.00024	0.00119	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ADCY5—osteoporosis	0.000237	0.00118	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGB—osteoporosis	0.000236	0.00118	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KL—osteoporosis	0.000233	0.00116	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSMA5—osteoporosis	0.000228	0.00114	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSMA2—osteoporosis	0.000228	0.00114	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—POMC—osteoporosis	0.000227	0.00113	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTHLH—osteoporosis	0.000223	0.00111	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BMP2—osteoporosis	0.000223	0.00111	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CALCA—osteoporosis	0.000223	0.00111	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6R—osteoporosis	0.000222	0.0011	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGB—osteoporosis	0.000219	0.00109	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—POMC—osteoporosis	0.000218	0.00109	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CALCA—osteoporosis	0.000213	0.00106	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSMA2—osteoporosis	0.000211	0.00105	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSMA5—osteoporosis	0.000211	0.00105	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—POMC—osteoporosis	0.000207	0.00103	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KL—osteoporosis	0.000203	0.00101	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—POMC—osteoporosis	0.000198	0.000986	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CALCA—osteoporosis	0.000197	0.000981	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KL—osteoporosis	0.000193	0.000962	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6R—osteoporosis	0.000193	0.000962	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—POMC—osteoporosis	0.000192	0.000956	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—POMC—osteoporosis	0.000188	0.000939	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6R—osteoporosis	0.000184	0.000916	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ADCY5—osteoporosis	0.000182	0.00091	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KL—osteoporosis	0.000179	0.00089	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SPP1—osteoporosis	0.000176	0.00088	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—POMC—osteoporosis	0.000174	0.000868	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6R—osteoporosis	0.00017	0.000847	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IRS2—osteoporosis	0.00016	0.000796	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ADCY5—osteoporosis	0.000159	0.000792	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LEP—osteoporosis	0.000156	0.000779	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SPP1—osteoporosis	0.000154	0.000766	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ADCY5—osteoporosis	0.000151	0.000754	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ESR1—osteoporosis	0.000149	0.000744	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SPP1—osteoporosis	0.000146	0.000729	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ADCY5—osteoporosis	0.00014	0.000697	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IRS1—osteoporosis	0.000139	0.000695	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IRS2—osteoporosis	0.000139	0.000693	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—osteoporosis	0.000136	0.000678	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SPP1—osteoporosis	0.000135	0.000675	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—POMC—osteoporosis	0.000134	0.000669	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IRS2—osteoporosis	0.000132	0.00066	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6R—osteoporosis	0.000131	0.000653	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—osteoporosis	0.00013	0.000647	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—osteoporosis	0.000129	0.000645	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1—osteoporosis	0.000129	0.000644	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—osteoporosis	0.000124	0.000616	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IRS2—osteoporosis	0.000122	0.00061	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IRS1—osteoporosis	0.000121	0.000605	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—osteoporosis	0.00012	0.000597	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—POMC—osteoporosis	0.000117	0.000582	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IRS1—osteoporosis	0.000115	0.000576	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—osteoporosis	0.000114	0.00057	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6R—osteoporosis	0.000114	0.000568	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1—osteoporosis	0.000112	0.00056	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—POMC—osteoporosis	0.000111	0.000554	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6R—osteoporosis	0.000108	0.000541	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1—osteoporosis	0.000107	0.000533	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IRS1—osteoporosis	0.000107	0.000533	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—POMC—osteoporosis	0.000103	0.000513	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6R—osteoporosis	0.0001	0.0005	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1—osteoporosis	9.9e-05	0.000493	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—osteoporosis	9.87e-05	0.000492	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—osteoporosis	8.59e-05	0.000428	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—osteoporosis	8.18e-05	0.000408	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—osteoporosis	7.76e-05	0.000387	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—osteoporosis	7.74e-05	0.000386	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—osteoporosis	7.57e-05	0.000377	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—osteoporosis	6.75e-05	0.000337	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—osteoporosis	6.74e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—osteoporosis	6.43e-05	0.000321	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—osteoporosis	6.41e-05	0.00032	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—osteoporosis	5.95e-05	0.000297	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—osteoporosis	5.93e-05	0.000296	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—osteoporosis	5.83e-05	0.000291	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—osteoporosis	5.08e-05	0.000253	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—osteoporosis	4.83e-05	0.000241	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—osteoporosis	4.47e-05	0.000223	CbGpPWpGaD
